Brookfield Asset Management Inc. Exelixis, Inc. Transaction History

Brookfield Asset Management Inc.

  • $14 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Sep 25, 2023
BUY
$16.3 - $19.41 $731,870 - $871,509
44,900 New
44,900 $871,000
Q1 2023

May 15, 2023
BUY
$16.3 - $19.41 $731,870 - $871,509
44,900 New
44,900 $871,000
Q3 2022

Nov 14, 2022
BUY
$15.68 - $22.27 $6.75 Million - $9.59 Million
430,542 New
430,542 $6.75 Million

Others Institutions Holding EXEL

# of Institutions
501
Shares Held
244M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Brookfield Asset Management Inc. Portfolio

Follow Brookfield Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brookfield Asset Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email